Marching Forward in Atopic Dermatitis

Faculty

Peter A. Lio, MD
Clinical Assistant Professor of Dermatology and Pediatrics
Feinberg School of Medicine
Northwestern University
Director, Chicago Integrative Eczema Center
Founding Partner, Medical Dermatology Associates of Chicago
Chicago, Illinois

Anne Marie Singh, MD
Associate Professor of Pediatrics
Director, Food Allergy Research and Education Center of Excellence
University of Wisconsin School of Medicine & Public Health
Madison, Wisconsin

Target Audience

The overall design of this activity addresses the needs of allergists/clinical immunologists and other clinicians who treat patients with moderate-to-severe atopic dermatitis.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

• Discuss clinically relevant pathophysiologic processes in atopic dermatitis
• Evaluate patients with moderate-to-severe atopic dermatitis for disease severity, comorbid conditions, and other biopsychosocial consequences
• Describe the clinical profiles and prescribing considerations for targeted therapies for atopic dermatitis
• Tailor therapy regimens for patients with moderate-to-severe atopic dermatitis based on ongoing symptoms, burdens, comorbidities, and shared clinical decision-making

Statement of Need/Program Overview

Atopic dermatitis is a common, chronic inflammatory disease that manifests primarily in the skin, although research has uncovered potentially deleterious effects in other organ systems throughout the body.^1,2 The disease-related physical and biopsychosocial burdens of this condition can have a substantial effect on patient and parent/caregiver quality of life.^3,4 Furthermore, people with atopic dermatitis have a higher likelihood of developing atopic comorbidities, also known as the atopic march.⁵ A better understanding of atopic dermatitis disease etiology has resulted in new insights into disease characterization and led to the development of targeted therapies.^6-8 As a result, the first biologic therapy is now FDA-approved to treat both adolescent and adult patients with moderate-to-severe atopic dermatitis, with other novel therapies in late-stage clinical development.^8-11 In this Interactive Exchange™ program, two experts in atopic dermatitis will review the pathophysiologic underpinnings of atopic dermatitis, new insights into disease characterization (including emerging research in distinct phenotypes and endotypes), common atopic and nonatopic comorbidities, and recommended management strategies for adolescents and adults with more severe disease.^5,12-15

References

1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015:66(suppl 1):8-16.
2. Brunner PM, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18-25.
3. Carroll CL, et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22(3):192-199.
4. Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.
5. Paller AS, et al. The atopic march and atopic multimorbidity: many trajectories, many pathways. J Allergy Clin Immunol. 2019;143(1):46-55.
6. Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858-873.
7. Gandhi NA, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
8. Renert-Yuval Y, Guttman-Yassky E. What’s new in atopic dermatitis. Dermatol Clin. 2019;37(2):205-213.
9. Wollenberg A, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135-141.
10. Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
11. Simpson EL, et al. Dupilumab efficacy and safety in adolescents with moderate-to-severe atopic dermatitis: results from a multicenter, randomized, placebo-controlled, double-blind, parallel-group, phase 3 study. Presented at the 27th EADV Congress; September 12-16, 2018; Paris, France. Poster 4640.
12. Czarnowicki T, et al. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1-11.
13. Sandhu JK, et al. Association between atopic dermatitis and suicidality: a systemic review and meta-analysis. JAMA Dermatol. 2019;155(2):178-187.
14. Brunner PM, et al. Increasing comorbidities suggset that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18-25.
15. Ariëns LFM, et al. Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy. Ther Adv Chronic Dis. 2018;9(9):159-170.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Instructions to Recieve Credit

In order to receive credit for this activity, the participant must score 70% or better on the posttest and complete the program evaluation.

System Requirements

PC
Microsoft Windows 2000 SE or above.
Flash Player Plugin (v7.0.1.9 or greater)
Internet Explorer (v5.5 or greater), or Firefox
Adobe Acrobat Reader*

MAC
MAC OS 10.2.8
Flash Player Plugin (v7.0.1.9 or greater)
Safari
Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh.

Fee Information

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Peter A. Lio, MD: Consultant/Independent Contractor: Abbvie Inc., Altus Labs, LLC, AOBiome, Dermavant Sciences, Inc., Eli Lilly and Company, Galderma Laboratories, L.P., IntraDerm Pharmaceuticals, Johnson & Johnson, Kiniksa Pharmaceuticals, Ltd., La Roche-Posay, Menlo Therapeutics Inc., Micreos BV, Pfizer Inc., Pierre Fabre Laboratories, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Theraplex, UCB Biopharma, Unilever. Grant/Research Support: Abbvie Inc., AOBiome, The Atopic Dermatitis Foundation, Regeneron Pharmaceuticals, Inc. Honoraria: Abbvie Inc., Altus Labs, LLC, AOBiome, Dermavant Sciences, Inc., Eli Lilly and Company, Galderma Laboratories, L.P., IntraDerm Pharmaceuticals, Johnson & Johnson, Kiniksa Pharmaceuticals, Ltd., La Roche-Posay, Menlo Therapeutics Inc., Micreos BV, Pfizer Inc., Pierre Fabre Laboratories, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Theraplex, UCB Biopharma, Unilever. Speakers Bureau: La Roche-Posay, Pfizer Inc., Pierre Fabre Laboratories, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme. Stock Shareholder: Altus Labs, LLC, Franklin Bioscience, Micreos BV, Syncere Skin Systems, Theraplex.

Anne Marie Singh, MD: Grant/Research Support: Food Allergy Research and Education; National Institutes of Health

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Lindsay Borvansky: Nothing to disclose.
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Stacey Ullman, MHS: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.